Group 1 - The core viewpoint of the report is that Gannee Pharmaceutical (603087.SH) is rated as a "buy" due to its strong performance and growth potential [2] - The company's formulation business is experiencing significant growth, benefiting from a synergistic effect of rising volume and price [2] - Gannee Pharmaceutical is advancing its globalization strategy, leading to rapid growth in international revenue [2] - The company is increasing its investment in research and development, achieving continuous breakthroughs [2]